Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 1998Journal of Clinical OncologyOpen Access

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.

View Full Paper
Ask AI
Bookmark
Share

Authors

Bob LöwenbergBob LöwenbergNorthwestern UniversitySSStefan SuciuUniversité Paris-SudEAE ArchimbaudHôpital Edouard Herriot

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Löwenberg et al. (1998) studied this question.

synapsesocial.com/papers/6a123fedea48cb855a3476c3https://doi.org/10.1200/jco.1998.16.3.872
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia1995 · 455 citations
  2. 2Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP)1981 · 79 citations
  3. 3On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.1989 · 388 citations
  4. 4Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia1994 · 1,441 citations
  5. 5Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia1985 · 70 citations